Liu Xiao, Ma Baozhen, Zhao Lingdi
Radiotherapy Department, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Immunotherapy Department, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Front Oncol. 2024 Apr 15;14:1342162. doi: 10.3389/fonc.2024.1342162. eCollection 2024.
Patients suffering from locally advanced gastric or gastroesophageal junction adenocarcinoma often face a high postoperative recurrence rate. Despite aggressive treatment, less than 50% survive beyond five years. Ongoing clinical studies are exploring ways to prolong patient survival, revealing that perioperative chemotherapy can extend both the period of recurrence-free survival and overall survival for this group of patients. Currently, combining chemotherapy and immune checkpoint inhibitors has become a critical treatment approach for advanced gastric or gastroesophageal junction adenocarcinoma. However, the effectiveness of this approach in locally advanced patients remains unverified. This article delves into the latest research concerning the use of perioperative chemotherapy coupled with immune checkpoint inhibitors in locally advanced gastric or gastroesophageal junction adenocarcinoma treatment, and highlights prospective challenges and discusses how to best identify patients who may benefit from combined chemotherapy and immune checkpoint inhibitor therapy.
患有局部晚期胃癌或胃食管交界腺癌的患者术后复发率往往很高。尽管进行了积极治疗，但五年生存率仍低于50%。正在进行的临床研究正在探索延长患者生存期的方法，结果表明围手术期化疗可以延长这类患者的无复发生存期和总生存期。目前，化疗与免疫检查点抑制剂联合使用已成为晚期胃癌或胃食管交界腺癌的关键治疗方法。然而，这种方法在局部晚期患者中的有效性仍未得到证实。本文深入探讨了围手术期化疗联合免疫检查点抑制剂用于局部晚期胃癌或胃食管交界腺癌治疗的最新研究，并强调了潜在挑战，讨论了如何最好地识别可能从联合化疗和免疫检查点抑制剂治疗中获益的患者。
